New indication of SonoVue® supports non-invasive assessment of female infertility through contrast-enhanced ultrasound in China
MILAN, Aug. 5, 2025 /PRNewswire/ -- Bracco Imaging, a global...
Recent lab results proved the Company’s hypothesis that disguising cancer cells to look like common infectious diseases can trick immune cells into attacking the malignant cells
Recent lab results proved the Company’s hypothesis that disguising cancer cells to look like common infectious diseases can trick immune cells into attacking the malignant cells
BEIJING, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the “Company,” “we,” “our” or “Pheton”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today issued the following statements in response to recent market volatility and a third-party publication that has raised questions and concerns among shareholders.
The global adhesives and sealants market size is expected to be worth USD 126.50 billion by 2034, increasing from USD 76.53 billion in 2025 and is growing at a CAGR of 5.75% from 2025 to 2034, fueled by green construction, EV adoption, and packaging innovations.
The global adhesives and sealants market size is expected to be worth USD 126.50 billion by 2034, increasing from USD 76.53 billion in 2025 and is growing at a CAGR of 5.75% from 2025 to 2034, fueled by green construction, EV adoption, and packaging innovations.
The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...
The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...
MADISON, Wis., July 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter of fiscal year 2025, ended...
SHANGHAI, July 28, 2025 /PRNewswire/ -- The multicenter, randomized controlled trial (RCT) results of the PANVIS-A® NeuroInterventional Robotic System—led by Professor Liu Jianmin (Changhai Hospital)...
TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2025 financial results after market close on Thursday, August 14, 2025.
Award and 300,000-Volt technological breakthrough position Avalanche to unlock key commercial revenue from fusion devices
SEATTLE, July 23, 2025 /PRNewswire/ -- Avalanche Energy, a fusion...
82km of drilling and $9M invested in resource development and exploration in Q4, FY25
PERTH, Western Australia, July 23, 2025 /CNW/ - Westgold Resources Limited...